SG11202112381VA - Compound used as kinase inhibitor and application thereof - Google Patents
Compound used as kinase inhibitor and application thereofInfo
- Publication number
- SG11202112381VA SG11202112381VA SG11202112381VA SG11202112381VA SG11202112381VA SG 11202112381V A SG11202112381V A SG 11202112381VA SG 11202112381V A SG11202112381V A SG 11202112381VA SG 11202112381V A SG11202112381V A SG 11202112381VA SG 11202112381V A SG11202112381V A SG 11202112381VA
- Authority
- SG
- Singapore
- Prior art keywords
- application
- compound used
- kinase inhibitor
- kinase
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910379104 | 2019-05-08 | ||
| PCT/CN2020/089067 WO2020224626A1 (fr) | 2019-05-08 | 2020-05-07 | Composé utilisé comme inhibiteur de kinase et son application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112381VA true SG11202112381VA (en) | 2021-12-30 |
Family
ID=73051434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112381VA SG11202112381VA (en) | 2019-05-08 | 2020-05-07 | Compound used as kinase inhibitor and application thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220089603A1 (fr) |
| EP (1) | EP3967696A4 (fr) |
| JP (1) | JP7420403B2 (fr) |
| KR (1) | KR20220007111A (fr) |
| CN (1) | CN112867717B (fr) |
| AU (1) | AU2020270303B2 (fr) |
| BR (1) | BR112021022255A2 (fr) |
| CA (1) | CA3142088C (fr) |
| IL (1) | IL287908A (fr) |
| MX (1) | MX2021013576A (fr) |
| SG (1) | SG11202112381VA (fr) |
| WO (1) | WO2020224626A1 (fr) |
| ZA (1) | ZA202109737B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114437077B (zh) * | 2020-11-04 | 2024-01-30 | 浙江同源康医药股份有限公司 | 用作激酶抑制剂的化合物及其应用 |
| CN114957259A (zh) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | 氰基取代的芳香双环类化合物及其应用 |
| WO2022262671A1 (fr) * | 2021-06-15 | 2022-12-22 | 中国医药研究开发中心有限公司 | Composé macro hétérocyclique et son utilisation médicale |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| WO2013189905A1 (fr) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Inhibiteurs de tankyrase de type pyrrolopyrazone |
| UY34893A (es) | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | Derivados de azaindol |
| KR102659741B1 (ko) | 2014-12-15 | 2024-04-23 | 주식회사 씨엠지제약 | 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도 |
| CN111171019A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| TW202033526A (zh) * | 2018-12-07 | 2020-09-16 | 大陸商貝達藥業股份有限公司 | 用作酪胺酸激酶抑制劑的化合物、包含其的藥物組合物及其用途 |
-
2020
- 2020-05-07 CA CA3142088A patent/CA3142088C/fr active Active
- 2020-05-07 SG SG11202112381VA patent/SG11202112381VA/en unknown
- 2020-05-07 KR KR1020217040056A patent/KR20220007111A/ko not_active Application Discontinuation
- 2020-05-07 MX MX2021013576A patent/MX2021013576A/es unknown
- 2020-05-07 AU AU2020270303A patent/AU2020270303B2/en active Active
- 2020-05-07 BR BR112021022255A patent/BR112021022255A2/pt unknown
- 2020-05-07 JP JP2021566283A patent/JP7420403B2/ja active Active
- 2020-05-07 CN CN202080004473.2A patent/CN112867717B/zh active Active
- 2020-05-07 WO PCT/CN2020/089067 patent/WO2020224626A1/fr unknown
- 2020-05-07 EP EP20802185.7A patent/EP3967696A4/fr active Pending
-
2021
- 2021-11-08 US US17/521,153 patent/US20220089603A1/en active Pending
- 2021-11-08 IL IL287908A patent/IL287908A/en unknown
- 2021-11-29 ZA ZA2021/09737A patent/ZA202109737B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3967696A4 (fr) | 2023-08-09 |
| US20220089603A1 (en) | 2022-03-24 |
| CA3142088C (fr) | 2023-02-28 |
| IL287908A (en) | 2022-01-01 |
| AU2020270303A1 (en) | 2022-01-06 |
| WO2020224626A1 (fr) | 2020-11-12 |
| CN112867717A (zh) | 2021-05-28 |
| JP7420403B2 (ja) | 2024-01-23 |
| KR20220007111A (ko) | 2022-01-18 |
| MX2021013576A (es) | 2021-12-15 |
| JP2022532141A (ja) | 2022-07-13 |
| AU2020270303B2 (en) | 2023-09-07 |
| EP3967696A1 (fr) | 2022-03-16 |
| CA3142088A1 (fr) | 2020-11-12 |
| WO2020224626A9 (fr) | 2020-12-30 |
| BR112021022255A2 (pt) | 2022-01-18 |
| ZA202109737B (en) | 2022-07-27 |
| CN112867717B (zh) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3806858A4 (fr) | Sels d'inhibiteurs de kinases et compositions associées | |
| SG11202011513RA (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| EP3672973A4 (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinase, compositions comprenant le composé hétérocyclique, et leurs procédés d'utilisation | |
| IL285178A (en) | compounds and their use | |
| EP3974422A4 (fr) | Composé utilisé comme inhibiteur de kinase ret et son utilisation | |
| EP3804707A4 (fr) | Inhibiteur de kinase | |
| EP3768267A4 (fr) | Composés inhibiteurs de kinase, compositions et procédés d'utilisation | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| IL285177A (en) | compounds and their use | |
| IL284745A (en) | Preparations containing 174 GPR suppressors and their uses | |
| EP3741758A4 (fr) | Composé inhibiteur de bromodomaine et son utilisation | |
| ZA202105752B (en) | Haloallylamine compounds and application thereof | |
| EP3906233A4 (fr) | Composés inhibiteurs de kinase, compositions et procédés d'utilisation | |
| EP3906028A4 (fr) | Composés inhibiteurs de kinase, compositions et méthodes d'utilisation | |
| EP4074699A4 (fr) | Composé utile en tant qu'inhibiteur de la kinase 9 dépendante de la cycline et son utilisation | |
| SG11202008705TA (en) | Heteroaryl compounds as kinase inhibitor | |
| IL284764A (en) | compounds and their uses | |
| ZA202110347B (en) | Bicyclic compound as rip-1 kinase inhibitor and application thereof | |
| IL285118A (en) | compounds and their uses | |
| EP4119553A4 (fr) | Composé utilisé comme inhibiteur de kinase et son utilisation | |
| EP4001276A4 (fr) | Inhibiteur de la kinase aurora et son utilisation | |
| IL304222A (en) | Alternative pyridotriazine compounds and their uses | |
| EP3915636A4 (fr) | Composé hydrazide et inhibiteur de kinase | |
| EP3717475A4 (fr) | Composés inhibiteurs de kinase, compositions et procédés d'utilisation | |
| EP3735404A4 (fr) | Composés inhibiteurs d'ask1 et utilisations associées |